High Disease Control Rates with Nivolumab Immunotherapy in Biliary Tract Cancer

The immune system is activated against cancer by new-generation immunotherapies (immune checkpoint inhibitors), which have shown efficacy and received approval for use in 15 major cancer types since their first approval in 2011; however, biliary tract cancer is not one of them. A multicenter clinical trial investigated one of the best-known of these immunotherapies, nivolumab (Opdivo), in a phase-II study to measure its efficacy in advanced, treatment-resistant biliary tract cancer, and the results were published in JAMA Oncology on 30 April.
Currently, there is no approved second-line systemic treatment for advanced biliary tract cancer. However, laboratory studies suggest that tumor-infiltrating CD8-positive T cells and PD-L1-positive tumor cells in the biliary tract cancer tumor microenvironment support the rationale for using anti-PD-1 blockade immunotherapy (such as nivolumab) in this cancer.
The study's result will be presented first, followed by the details: in this multicenter phase-II study of 54 patients with advanced, treatment-resistant biliary tract cancer, the investigators reported objective responses in 10 patients and a disease control rate of 59%. Independent radiologic review reported objective responses in 5 patients and a disease control rate of 50%. This means that nivolumab may be effective in patients with advanced, treatment-resistant biliary tract cancer and should be investigated further in a phase-III study.

This single-arm, multicenter phase 2 study of nivolumab enrolled 54 patients who had received at least 1 and no more than 3 previous lines of treatment. Patients received 240 mg of intravenous nivolumab every 2 weeks for 16 weeks, followed by 480 mg intravenously every 4 weeks until disease progression or unacceptable side effects occurred.
The primary endpoint measured in the study was the investigator-assessed objective response rate, and the secondary endpoints were progression-free survival, overall survival, and the frequency of side effects.
Findings
- A total of 54 patients (27 men and 27 women; median age 65 years) were assessed for objective response using radiologic imaging.
- The investigator-assessed objective response rate was 22% (10 of 46), and the disease control rate was 59% (27 of 46).
- The objective response rate measured by the central independent review team was 11% (5 of 46), and with a disease control rate of 50% (23 of 46%), an objective response rate of 11% (5 of 46) was found.
- All patients who responded to treatment had dMMR (DNA mismatch repair deficiency) tumors.
- As most patients among half of the responders were still responding, the median duration of response had not been reached, and patients were followed for a median of 12.4 months.
- Median progression-free survival was 3.7 months, and median overall survival was 14.2 months.
- PD-L1 positivity was found to reduce the risk of disease progression by 77%.
- The most common serious (grade 3 or 4) treatment-related side effects were hyponatremia (3 of 54 patients [6%]) and increased alkaline phosphatase (2 of 54 [4%]).
Conclusion
This study found that nivolumab was well tolerated in patients with advanced, treatment-resistant biliary tract cancer and showed long-lasting efficacy in some patients. Further studies are needed to confirm the findings, improve treatment selection, and evaluate biomarkers that may identify who will benefit from immunotherapy.
Sources
A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer.
JAMA Oncology, 30 April 2020.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.